Kurt’s expertise and track record is in leading research programs, preclinical studies from concept to commercial launch including writing sections for IND and NDA for companies like Anacor Pharmaceuticals (acquired by Pfizer), Pfizer, Iconix Pharmaceuticals (acquired by Entelos) and earlier in his career at Roche Biosciences as Deputy Therapeutic Head, Inflammation/Immunomodulation. Roche acquired Syntex where he conducted drug discovery research. His expertise in writing and recruiting partners for non-dilutive grants has already resulted in a successful SBIR application for Synbal.

Kurt has a PhD degree in Biochemistry from the University of Wisconsin-Madison and a B.S.-Biochemistry (with Honors) from North Carolina State University in Raleigh. Dr. Kurt Jarnagin has 58 publications and 11 granted patents and was awarded the: E.K. Frey-E. Werle, International Kinin Chemistry Prize of the Henning-Voight Foundation of Germany, 1993.